Skip to main content

Fate Therapeutics, Inc. (FATE)

NASDAQ: FATE · IEX Real-Time Price · USD
58.00
-0.16 (-0.28%)
After-hours:Oct 25, 2021 7:07 PM EDT
58.16
-0.84 (-1.42%)
At close: Oct 25, 4:00 PM
Market Cap5.47B
Revenue (ttm)48.01M
Net Income (ttm)-212.02M
Shares Out94.33M
EPS (ttm)-2.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,391,820
Open58.91
Previous Close59.00
Day's Range57.17 - 59.77
52-Week Range42.64 - 121.16
Beta1.73
AnalystsBuy
Price Target108.79 (+87.1%)
Est. Earnings DateNov 4, 2021

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors...

IndustryBiotechnology
IPO DateOct 1, 2013
CEOWilliam Rastetter
Employees356
Stock ExchangeNASDAQ
Ticker SymbolFATE
Full Company Profile

Financial Performance

In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 108.79, which is an increase of 87.05% from the latest price.

Price Target
$108.79
(87.05% upside)
Analyst Consensus: Buy

News

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

16 hours ago - GlobeNewsWire

Tentarix Biotherapeutics Emerges with $50 Million Series A

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCa...

1 week ago - Business Wire

3 Biotech Stocks to Watch Now

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

Other symbols:ACADPIRS
1 week ago - Benzinga

Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for pa...

3 weeks ago - GlobeNewsWire

Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain

Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.

1 month ago - The Motley Fool

Cathie Wood Makes Adjustments to Portfolio in August

Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.

Other symbols:DYNSKVSBMASSQSIVUZI
1 month ago - GuruFocus

Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for c...

1 month ago - GlobeNewsWire

Why Fate Therapeutics Stock Is Sliding Today

The positive results the company announced after the bell yesterday didn't meet some lofty expectations.

2 months ago - The Motley Fool

Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response

Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021 American Society of Clinical Oncology M...

2 months ago - Benzinga

Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Ce...

10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rit...

2 months ago - GlobeNewsWire

FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

FATE reports a wider loss on increased R&D expenses in the second quarter.

Other symbols:BMYGILDJNJ
2 months ago - Zacks Investment Research

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -11.54% and 89.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal Maste...

2 months ago - GlobeNewsWire

Cathie Wood's ARK Invest Buys Over 240,000 Shares of Fate Therapeutics

A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Tuesday.

2 months ago - 24/7 Wall Street

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iP...

Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

2 months ago - GlobeNewsWire

Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth

Hot biotech stocks to watch right now as cancer treatments make headlines in 2021. The post Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth appeared first on Penny Stocks to Buy, ...

Other symbols:GTBPTEVA
2 months ago - PennyStocks

Did You See What Cathie Wood Bought on Wednesday?

ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.

Other symbols:DKNGZM
3 months ago - The Motley Fool

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-deriv...

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

3 months ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

3 months ago - GlobeNewsWire

Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday.

3 months ago - 24/7 Wall Street

Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

4 months ago - GlobeNewsWire

The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data

The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading da...

4 months ago - Forbes

Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21

Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell lymphoma. Data were presented at the 2021 Am...

4 months ago - Benzinga